Korean Journal of Radiology

The Korean Society of Radiology (대한영상의학회)
권호 표지
DOI QR코드

DOI QR Code

Yttrium-90 Selective Internal Radiation Therapy with Glass Microspheres for Hepatocellular Carcinoma: Current and Updated Literature Review

  • Lee, Edward Wolfgang (Division of Interventional Radiology, Department of Radiology, UCLA Medical Center, David Geffen School of Medicine at UCLA) ;
  • Alanis, Lourdes (Division of Interventional Radiology, Department of Radiology, UCLA Medical Center, David Geffen School of Medicine at UCLA) ;
  • Cho, Sung-Ki (Division of Interventional Radiology, Department of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Saab, Sammy (Division of Hepatology, Department of Medicine, Pfleger Liver Institute, University of California at Los Angeles)
  • Received : 2015.09.07
  • Accepted : 2016.03.20
  • Published : 2016.07.01
⟨ Previous Next ⟩

Abstract

Hepatocellular carcinoma is the most common primary liver cancer and it represents the majority of cancer-related deaths in the world. More than 70% of patients present at an advanced stage, beyond potentially curative options. Ytrrium-90 selective internal radiation therapy (Y90-SIRT) with glass microspheres is rapidly gaining acceptance as a potential therapy for intermediate and advanced stage primary hepatocellular carcinoma and liver metastases. The technique involves delivery of Y90 infused glass microspheres via the hepatic arterial blood flow to the appropriate tumor. The liver tumor receives a highly concentrated radiation dose while sparing the healthy liver parenchyma due to its preferential blood supply from portal venous blood. There are two commercially available devices: TheraSphere$^{(R)}$ and SIR-Spheres$^{(R)}$. Although, Y90-SIRT with glass microspheres improves median survival in patients with intermediate and advanced hepatocellular carcinoma and has the potential to downstage hepatocellular carcinoma so that the selected candidates meet the transplantable criteria, it has not gained widespread acceptance due to the lack of large randomized controlled trials. Currently, there are various clinical trials investigating the use of Y90-SIRT with glass microspheres for treatment of hepatocellular carcinoma and the outcomes of these trials may result in the incorporation of Y90-SIRT with glass microspheres into the treatment guidelines as a standard therapy option for patients with intermediate and advanced stage hepatocellular carcinoma.

Keywords

References

  1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-E386 https://doi.org/10.1002/ijc.29210
  2. Cancer Facts & Figures 2014. American Cancer Society. http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2014/. Accessed December 13, 2015
  3. European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908-943 https://doi.org/10.1016/j.jhep.2011.12.001
  4. Maida M, Orlando E, Camma C, Cabibbo G. Staging systems of hepatocellular carcinoma: a review of literature. World J Gastroenterol 2014;20:4141-4150 https://doi.org/10.3748/wjg.v20.i15.4141
  5. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003;37:429-442 https://doi.org/10.1053/jhep.2003.50047
  6. ClinicalTrials.gov. http://clinicaltrials.gov/ct2/home. Accessed December 13, 2015
  7. Vesselle G, Petit I, Boucebci S, Rocher T, Velasco S, Tasu JP. Radioembolization with yttrium-90 microspheres work up: practical approach and literature review. Diagn Interv Imaging 2015;96:547-562 https://doi.org/10.1016/j.diii.2014.03.014
  8. Salem R, Lewandowski RJ, Sato KT, Atassi B, Ryu RK, Ibrahim S, et al. Technical aspects of radioembolization with 90Y microspheres. Tech Vasc Interv Radiol 2007;10:12-29 https://doi.org/10.1053/j.tvir.2007.08.001
  9. Memon K, Lewandowski RJ, Riaz A, Salem R. Yttrium 90 microspheres for the treatment of hepatocellular carcinoma. Recent Results Cancer Res 2013;190:207-224
  10. Volchok HL, Kulp JL. Half-life of yttrium-90. Phys Rev 1955;97:102 https://doi.org/10.1103/PhysRev.97.102
  11. Salem R, Lewandowski RJ, Atassi B, Gordon SC, Gates VL, Barakat O, et al. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol 2005;16:1627-1639 https://doi.org/10.1097/01.RVI.0000184594.01661.81
  12. TheraSphere HDE Approval. US Food and Drug Administration. http://www.fda.gov/ohrms/dockets/dailys/00/jan00/010500/aav0001.pdf. Accessed December 13, 2015
  13. Medical Devices SIR-Spheres. U.S. Food and Drug Administration. http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ ucm083605.htm. Accessed December 13, 2015
  14. Riaz A, Awais R, Salem R. Side effects of yttrium-90 radioembolization. Front Oncol 2014;4:198
  15. Lau WY, Kennedy AS, Kim YH, Lai HK, Lee RC, Leung TW, et al. Patient selection and activity planning guide for selective internal radiotherapy with yttrium-90 resin microspheres. Int J Radiat Oncol Biol Phys 2012;82:401-407 https://doi.org/10.1016/j.ijrobp.2010.08.015
  16. Salem R, Mazzaferro V, Sangro B. Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: biological lessons, current challenges, and clinical perspectives. Hepatology 2013;58:2188-2197 https://doi.org/10.1002/hep.26382
  17. Salem ME, Jain N, Dyson G, Taylor S, El-Refai SM, Choi M, et al. Radiographic parameters in predicting outcome of patients with hepatocellular carcinoma treated with yttrium-90 microsphere radioembolization. ISRN Oncol 2013;2013:538376
  18. Theysohn JM, Muller S, Schlaak JF, Ertle J, Schlosser TW, Bockisch A, et al. Selective internal radiotherapy (SIRT) of hepatic tumors: how to deal with the cystic artery. Cardiovasc Intervent Radiol 2013;36:1015-1022 https://doi.org/10.1007/s00270-012-0474-1
  19. McWilliams JP, Kee ST, Loh CT, Lee EW, Liu DM. Prophylactic embolization of the cystic artery before radioembolization: feasibility, safety, and outcomes. Cardiovasc Intervent Radiol 2011;34:786-792 https://doi.org/10.1007/s00270-010-0021-x
  20. Powerski MJ, Scheurig-Munkler C, Banzer J, Schnapauff D, Hamm B, Gebauer B. Clinical practice in radioembolization of hepatic malignancies: a survey among interventional centers in Europe. Eur J Radiol 2012;81:e804-e811 https://doi.org/10.1016/j.ejrad.2012.04.004
  21. Kennedy A. Radioembolization of hepatic tumors. J Gastrointest Oncol 2014;5:178-189
  22. Physicians Package Insert. TheraSphere. http://www. therasphere.com/physicians_us/package_insert.asp. Accessed December 13, 2015
  23. Salem R, Lewandowski R, Roberts C, Goin J, Thurston K, Abouljoud M, et al. Use of Yttrium-90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis. J Vasc Interv Radiol 2004;15:335-345 https://doi.org/10.1097/01.RVI.0000123319.20705.92
  24. Kulik LM, Carr BI, Mulcahy MF, Lewandowski RJ, Atassi B, Ryu RK, et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 2008;47:71-81
  25. McCann JW, Larkin AM, Martino LJ, Eschelman DJ, Gonsalves CF, Brown DB. Radiation emission from patients treated with selective hepatic radioembolization using yttrium-90 microspheres: are contact restrictions necessary? J Vasc Interv Radiol 2012;23:661-667 https://doi.org/10.1016/j.jvir.2012.01.070
  26. Riaz A, Memon K, Miller FH, Nikolaidis P, Kulik LM, Lewandowski RJ, et al. Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation. J Hepatol 2011;54:695-704 https://doi.org/10.1016/j.jhep.2010.10.004
  27. Duke E, Deng J, Ibrahim SM, Lewandowski RJ, Ryu RK, Sato KT, et al. Agreement between competing imaging measures of response of hepatocellular carcinoma to yttrium-90 radioembolization. J Vasc Interv Radiol 2010;21:515-521 https://doi.org/10.1016/j.jvir.2009.11.020
  28. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. http://whqlibdoc.who.int/ offset/WHO_OFFSET_48.pdf. Accessed December 13, 2015
  29. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216 https://doi.org/10.1093/jnci/92.3.205
  30. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010;30:52-60 https://doi.org/10.1055/s-0030-1247132
  31. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421-430 https://doi.org/10.1016/S0168-8278(01)00130-1
  32. Rhee TK, Naik NK, Deng J, Atassi B, Mulcahy MF, Kulik LM, et al. Tumor response after yttrium-90 radioembolization for hepatocellular carcinoma: comparison of diffusion-weighted functional MR imaging with anatomic MR imaging. J Vasc Interv Radiol 2008;19:1180-1186 https://doi.org/10.1016/j.jvir.2008.05.002
  33. Weng Z, Ertle J, Zheng S, Lauenstein T, Mueller S, Bockisch A, et al. A new model to estimate prognosis in patients with hepatocellular carcinoma after Yttrium-90 radioembolization. PLoS One 2013;8:e82225 https://doi.org/10.1371/journal.pone.0082225
  34. Carr BI. Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. Liver Transpl 2004;10(2 Suppl 1):S107-S110 https://doi.org/10.1002/lt.20036
  35. Padia SA, Kwan SW, Roudsari B, Monsky WL, Coveler A, Harris WP. Superselective yttrium-90 radioembolization for hepatocellular carcinoma yields high response rates with minimal toxicity. J Vasc Interv Radiol 2014;25:1067-1073 https://doi.org/10.1016/j.jvir.2014.03.030
  36. Sangro B, Gil-Alzugaray B, Rodriguez J, Sola I, Martinez-Cuesta A, Viudez A, et al. Liver disease induced by radioembolization of liver tumors: description and possible risk factors. Cancer 2008;112:1538-1546 https://doi.org/10.1002/cncr.23339
  37. Kennedy AS, McNeillie P, Dezarn WA, Nutting C, Sangro B, Wertman D, et al. Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumors. Int J Radiat Oncol Biol Phys 2009;74:1494-1500 https://doi.org/10.1016/j.ijrobp.2008.10.005
  38. Sangro B, Bilbao JI, Inarrairaegui M, Rodriguez M, Garrastachu P, Martinez-Cuesta A. Treatment of hepatocellular carcinoma by radioembolization using 90Y microspheres. Dig Dis 2009;27:164-169 https://doi.org/10.1159/000218349
  39. Atassi B, Bangash AK, Lewandowski RJ, Ibrahim S, Kulik L, Mulcahy MF, et al. Biliary sequelae following radioembolization with Yttrium-90 microspheres. J Vasc Interv Radiol 2008;19:691-697 https://doi.org/10.1016/j.jvir.2008.01.003
  40. Salem R, Parikh P, Atassi B, Lewandowski RJ, Ryu RK, Sato KT, et al. Incidence of radiation pneumonitis after hepatic intra-arterial radiotherapy with yttrium-90 microspheres assuming uniform lung distribution. Am J Clin Oncol 2008;31:431-438 https://doi.org/10.1097/COC.0b013e318168ef65
  41. Murthy R, Brown DB, Salem R, Meranze SG, Coldwell DM, Krishnan S, et al. Gastrointestinal complications associated with hepatic arterial Yttrium-90 microsphere therapy. J Vasc Interv Radiol 2007;18:553-561; quiz 562 https://doi.org/10.1016/j.jvir.2007.02.002
  42. U.S. Preventive Services Task Force Procedure Manual. AHRQ Publication No. 08-05118-EF. USPSTF. http://www.uspreventiveservicestaskforce.org/Home/GetFile/6/7/procmanual/pdf. Accessed December 13, 2015
  43. Hilgard P, Hamami M, Fouly AE, Scherag A, Muller S, Ertle J, et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology 2010;52:1741-1749 https://doi.org/10.1002/hep.23944
  44. Sangro B, Salem R, Kennedy A, Coldwell D, Wasan H. Radioembolization for hepatocellular carcinoma: a review of the evidence and treatment recommendations. Am J Clin Oncol 2011;34:422-431 https://doi.org/10.1097/COC.0b013e3181df0a50
  45. Salem R, Lewandowski RJ, Kulik L, Wang E, Riaz A, Ryu RK, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2011;140:497-507.e2 https://doi.org/10.1053/j.gastro.2010.10.049
  46. Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010;138:52-64 https://doi.org/10.1053/j.gastro.2009.09.006
  47. Mazzaferro V, Sposito C, Bhoori S, Romito R, Chiesa C, Morosi C, et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology 2013;57:1826-1837 https://doi.org/10.1002/hep.26014
  48. Gaba RC, Riaz A, Lewandowski RJ, Ibrahim SM, Ryu RK, Sato KT, et al. Safety of yttrium-90 microsphere radioembolization in patients with biliary obstruction. J Vasc Interv Radiol 2010;21:1213-1218 https://doi.org/10.1016/j.jvir.2010.04.013
  49. Theysohn JM, Ertle J, Muller S, Schlaak JF, Nensa F, Sipilae S, et al. Hepatic volume changes after lobar selective internal radiation therapy (SIRT) of hepatocellular carcinoma. Clin Radiol 2014;69:172-178 https://doi.org/10.1016/j.crad.2013.09.009
  50. Teo JY, Goh BK, Cheah FK, Allen JC, Lo RH, Ng DC, et al. Underlying liver disease influences volumetric changes in the spared hemiliver after selective internal radiation therapy with 90Y in patients with hepatocellular carcinoma. J Dig Dis 2014;15:444-450 https://doi.org/10.1111/1751-2980.12162
  51. Lambert B, Sturm E, Mertens J, Oltenfreiter R, Smeets P, Troisi R, et al. Intra-arterial treatment with $^{90}Y$ microspheres for hepatocellular carcinoma: 4 years experience at the Ghent University Hospital. Eur J Nucl Med Mol Imaging 2011;38:2117-2124 https://doi.org/10.1007/s00259-011-1881-2
  52. Khalaf H, Alsuhaibani H, Al-Sugair A, Al-Mana H, Al-Mutawa A, Al-Kadhi Y, et al. Use of yttrium-90 microsphere radioembolization of hepatocellular carcinoma as downstaging and bridge before liver transplantation: a case report. Transplant Proc 2010;42:994-998 https://doi.org/10.1016/j.transproceed.2010.03.019
  53. Luna LE, Kwo PY, Roberts LR, Mettler TA, Gansen DN, Andrews JC, et al. Liver transplantation after radioembolization in a patient with unresectable HCC. Nat Rev Gastroenterol Hepatol 2009;6:679-683 https://doi.org/10.1038/nrgastro.2009.165
  54. Tohme S, Sukato D, Chen HW, Amesur N, Zajko AB, Humar A, et al. Yttrium-90 radioembolization as a bridge to liver transplantation: a single-institution experience. J Vasc Interv Radiol 2013;24:1632-1638 https://doi.org/10.1016/j.jvir.2013.07.026
  55. Kulik LM, Atassi B, van Holsbeeck L, Souman T, Lewandowski RJ, Mulcahy MF, et al. Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol 2006;94:572-586 https://doi.org/10.1002/jso.20609
  56. Lewandowski RJ, Kulik LM, Riaz A, Senthilnathan S, Mulcahy MF, Ryu RK, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant 2009;9:1920-1928 https://doi.org/10.1111/j.1600-6143.2009.02695.x
  57. Donahue LA, Kulik L, Baker T, Ganger DR, Gupta R, Memon K, et al. Yttrium-90 radioembolization for the treatment of unresectable hepatocellular carcinoma in patients with transjugular intrahepatic portosystemic shunts. J Vasc Interv Radiol 2013;24:74-80 https://doi.org/10.1016/j.jvir.2012.09.030
  58. Ibrahim SM, Kulik L, Baker T, Ryu RK, Mulcahy MF, Abecassis M, et al. Treating and downstaging hepatocellular carcinoma in the caudate lobe with yttrium-90 radioembolization. Cardiovasc Intervent Radiol 2012;35:1094-1101 https://doi.org/10.1007/s00270-011-0292-x
  59. Garin E, Lenoir L, Rolland Y, Edeline J, Mesbah H, Laffont S, et al. Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results. J Nucl Med 2012;53:255-263 https://doi.org/10.2967/jnumed.111.094235
  60. Edeline J, Lenoir L, Boudjema K, Rolland Y, Boulic A, Le Du F, et al. Volumetric changes after (90)y radioembolization for hepatocellular carcinoma in cirrhosis: an option to portal vein embolization in a preoperative setting? Ann Surg Oncol 2013;20:2518-2525 https://doi.org/10.1245/s10434-013-2906-9
  61. Riaz A, Gates VL, Atassi B, Lewandowski RJ, Mulcahy MF, Ryu RK, et al. Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization. Int J Radiat Oncol Biol Phys 2011;79:163-171 https://doi.org/10.1016/j.ijrobp.2009.10.062
  62. Lance C, McLennan G, Obuchowski N, Cheah G, Levitin A, Sands M, et al. Comparative analysis of the safety and efficacy of transcatheter arterial chemoembolization and yttrium-90 radioembolization in patients with unresectable hepatocellular carcinoma. J Vasc Interv Radiol 2011;22:1697-1705 https://doi.org/10.1016/j.jvir.2011.08.013
  63. Moreno-Luna LE, Yang JD, Sanchez W, Paz-Fumagalli R, Harnois DM, Mettler TA, et al. Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma. Cardiovasc Intervent Radiol 2013;36:714-723 https://doi.org/10.1007/s00270-012-0481-2
  64. El Fouly A, Ertle J, El Dorry A, Shaker MK, Dechene A, Abdella H, et al. In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization? Liver Int 2015;35:627-635 https://doi.org/10.1111/liv.12637
  65. Salem R, Gilbertsen M, Butt Z, Memon K, Vouche M, Hickey R, et al. Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization. Clin Gastroenterol Hepatol 2013;11:1358-1365.e1 https://doi.org/10.1016/j.cgh.2013.04.028
  66. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390 https://doi.org/10.1056/NEJMoa0708857
  67. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34 https://doi.org/10.1016/S1470-2045(08)70285-7
  68. Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol 2012;57:821-829 https://doi.org/10.1016/j.jhep.2012.06.014
  69. Pressiani T, Boni C, Rimassa L, Labianca R, Fagiuoli S, Salvagni S, et al. Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis. Ann Oncol 2013;24:406-411 https://doi.org/10.1093/annonc/mds343
  70. Sangro B, Inarrairaegui M, Bilbao JI. Radioembolization for hepatocellular carcinoma. J Hepatol 2012;56:464-473
  71. Grady ED. Internal radiation therapy of hepatic cancer. Dis Colon Rectum 1979;22:371-375 https://doi.org/10.1007/BF02586901
  72. Bal CS, Kumar A. Radionuclide therapy for hepatocellular carcinoma: indication, cost and efficacy. Trop Gastroenterol 2008;29:62-70
  73. Ariel IM. Treatment of inoperable primary pancreatic and liver cancer by the intra-arterial administration of radioactive isotopes (Y90 radiating microspheres). Ann Surg 1965;162:267-278 https://doi.org/10.1097/00000658-196508000-00018
  74. Pons F, Varela M, Llovet JM. Staging systems in hepatocellular carcinoma. HPB (Oxford) 2005;7:35-41 https://doi.org/10.1080/13651820410024058
  75. Leung TW, Lau WY, Ho SK, Ward SC, Chow JH, Chan MS, et al. Radiation pneumonitis after selective internal radiation treatment with intraarterial 90yttrium-microspheres for inoperable hepatic tumors. Int J Radiat Oncol Biol Phys 1995;33:919-924 https://doi.org/10.1016/0360-3016(95)00039-3
  76. Carr BI, Kondragunta V, Buch SC, Branch RA. Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study. Cancer 2010;116:1305-1314 https://doi.org/10.1002/cncr.24884
  77. Woodall CE, Scoggins CR, Ellis SF, Tatum CM, Hahl MJ, Ravindra KV, et al. Is selective internal radioembolization safe and effective for patients with inoperable hepatocellular carcinoma and venous thrombosis? J Am Coll Surg 2009;208:375-382 https://doi.org/10.1016/j.jamcollsurg.2008.12.009
  78. Goin J, Dancey JE, Roberts C, Sickles CJ, Leung DA, Soulen MC. Comparison of postembolization syndrome in the treatment of patients with unresectable hepatocellular carcinoma: trans-catheter chemo-embolization versus yttrium-90 glass microspheres. World J Nucl Med 2004;3:49-56
  79. Dancey JE, Shepherd FA, Paul K, Sniderman KW, Houle S, Gabrys J, et al. Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. J Nucl Med 2000;41:1673-1681
  80. Geschwind JF, Salem R, Carr BI, Soulen MC, Thurston KG, Goin KA, et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology 2004;127(5 Suppl 1):S194-S205 https://doi.org/10.1053/j.gastro.2004.09.034
  81. Goin JE, Salem R, Carr BI, Dancey JE, Soulen MC, Geschwind JF, et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: a risk-stratification analysis. J Vasc Interv Radiol 2005;16(2 Pt 1):195-203 https://doi.org/10.1097/01.RVI.0000142602.79459.90
  82. Goin JE, Salem R, Carr BI, Dancey JE, Soulen MC, Geschwind JF, et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicities. J Vasc Interv Radiol 2005;16(2 Pt 1):205-213 https://doi.org/10.1097/01.RVI.00001142592.89564.F9

Cited by

  1. Review of the Development of Methods for Characterization of Microspheres for Use in Embolotherapy: Translating Bench to Cathlab vol.6, pp.9, 2017, https://doi.org/10.1002/adhm.201601291
  2. Personnel dose reduction in90Y microspheres liver-directed radioembolization: from interventional radiology suite to patient ward vol.90, pp.1071, 2016, https://doi.org/10.1259/bjr.20160591
  3. Imaging Evaluation Following 90 Y Radioembolization of Liver Tumors: What Radiologists Should Know vol.19, pp.2, 2016, https://doi.org/10.3348/kjr.2018.19.2.209
  4. Comparison of the Efficacy and Prognostic Factors of Transarterial Chemoembolization Plus Microwave Ablation versus Transarterial Chemoembolization Alone in Patients with a Large Solitary or Multinodu vol.19, pp.2, 2018, https://doi.org/10.3348/kjr.2018.19.2.237
  5. Prognostic Factors in Overall Survival of Patients with Unresectable Intrahepatic Cholangiocarcinoma Treated by Means of Yttrium-90 Radioembolization: Results in Therapy-Naïve Patients vol.41, pp.5, 2016, https://doi.org/10.1007/s00270-017-1871-2
  6. Chemoembolization related to good survival for selected patients with hepatocellular carcinoma invading segmental portal vein vol.38, pp.9, 2016, https://doi.org/10.1111/liv.13719
  7. Radioactive Main Group and Rare Earth Metals for Imaging and Therapy vol.119, pp.2, 2016, https://doi.org/10.1021/acs.chemrev.8b00294
  8. Expected and Unexpected Imaging Findings after 90Y Transarterial Radioembolization for Liver Tumors vol.39, pp.2, 2019, https://doi.org/10.1148/rg.2019180095
  9. Comparison of Radioembolization and Sorafenib for the Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Systematic Review and Meta-Analysis of Safety and Efficacy vol.20, pp.3, 2016, https://doi.org/10.3348/kjr.2018.0496
  10. Brachytherapy using elastin-like polypeptide with different concentrations of 131I for treatment of VX2 liver tumor in rabbits vol.27, pp.8, 2016, https://doi.org/10.11569/wcjd.v27.i8.485
  11. Clinical Applications of Technetium-99m Quantitative Single-Photon Emission Computed Tomography/Computed Tomography vol.53, pp.3, 2016, https://doi.org/10.1007/s13139-019-00588-9
  12. Therapeutic advances for patients with intermediate hepatocellular carcinoma vol.234, pp.8, 2016, https://doi.org/10.1002/jcp.28019
  13. Hypofractionated particle beam therapy for hepatocellular carcinoma-a brief review of clinical effectiveness vol.11, pp.8, 2016, https://doi.org/10.4251/wjgo.v11.i8.579
  14. Outpatient Yttrium-90 microsphere radioembolization: assessment of radiation safety and quantification of post-treatment adverse events causing hospitalization vol.125, pp.10, 2016, https://doi.org/10.1007/s11547-020-01180-4
  15. Timeline of Translational Formulation Technologies for Cancer Therapy: Successes, Failures, and Lessons Learned Therefrom vol.12, pp.11, 2016, https://doi.org/10.3390/pharmaceutics12111028
  16. Clinical Management of Liver Cancer in India and Other Developing Nations: A Focus on Radiation Based Strategies vol.9, pp.2, 2016, https://doi.org/10.1007/s40487-021-00154-4